Literature DB >> 16997354

Direct and indirect evidence for the reversibility of cirrhosis.

Jeanne Serpaggi1, Françoise Carnot, Bertrand Nalpas, Danièle Canioni, Jérôme Guéchot, Pascal Lebray, Anaïs Vallet-Pichard, Hélène Fontaine, Pierre Bedossa, Stanislas Pol.   

Abstract

The aim of this study was to assess the reversibility of cirrhosis after therapy in a large series of patients with cirrhosis from various etiologies. We performed a retrospective study of 113 patients with biopsy-proven cirrhosis who underwent specific therapy and follow-up biopsies. Two pathologists performed blinded analyses of indirect biochemical and morphological signs of cirrhosis. Fourteen (12.4%) of the 113 cirrhotic patients had biopsy-proven disappearance of cirrhosis, defined as a decrease of 2 or greater in their METAVIR fibrosis score: 8 were related to hepatitis C virus, 3 to hepatitis B virus, and 3 to autoimmune cirrhosis. Necro-inflammatory activity decreased from 2.4 +/- 0.65 to 0.85 +/- 0.9 (P = .004), and fibrosis from 4 to 1.7 +/- 0.61 (P = .001). Prothrombin time (n = 1), platelet count (n = 2), serum albumin level (n = 2), and ultrasound abnormalities (n = 6) normalized in patients who had initial abnormalities. Hyaluronic acid and procollagen type III serum level decreased in all. In the 11 patients with regression of viral cirrhosis, 2 were nonresponders and 9 were responders, including 2 relapsers. The 3 patients with regressive autoimmune cirrhosis were complete responders to immunosupressive therapy. Using repeated liver biopsies, clinicobiochemical, radiologic, and endoscopic tests, we provide evidence for potential reversibility of cirrhosis after long-lasting suppression of the necro-inflammatory activity of liver disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16997354     DOI: 10.1016/j.humpath.2006.07.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  Reversing Advanced Hepatic Fibrosis in NASH: Clearly Possible, but Widely at Hand?

Authors:  Stephen H Caldwell; Curtis K Argo
Journal:  Dig Dis Sci       Date:  2015-01-25       Impact factor: 3.199

Review 2.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

3.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

4.  Versican: a novel modulator of hepatic fibrosis.

Authors:  Terence N Bukong; Sean B Maurice; Barinder Chahal; David F Schaeffer; Paul J Winwood
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

5.  Fibrosis Regression Explains Differences in Outcome in HIV-/HCV-Coinfected Patients with Cirrhosis After Sustained Virological Response.

Authors:  José Luis Casado; María Angeles Esteban; Sara Bañón; Ana Moreno; María J Perez-Elías; María Luisa Mateos; Santiago Moreno; Carmen Quereda
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

Review 6.  Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.

Authors:  Michael Zeisberg; Raghu Kalluri
Journal:  Am J Physiol Cell Physiol       Date:  2012-12-19       Impact factor: 4.249

7.  Reversal of liver fibrosis.

Authors:  Mona H Ismail; Massimo Pinzani
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

Review 8.  Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.

Authors:  Prodromos Hytiroglou; Neil D Theise
Journal:  Virchows Arch       Date:  2018-03-27       Impact factor: 4.064

9.  Accuracy of routine clinical ultrasound for staging of liver fibrosis.

Authors:  Chih-Ching Choong; Sudhakar K Venkatesh; Edwin P Y Siew
Journal:  J Clin Imaging Sci       Date:  2012-09-25

10.  Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

Authors:  Harinder S Chahal; Elliot A Marseille; Jeffrey A Tice; Steve D Pearson; Daniel A Ollendorf; Rena K Fox; James G Kahn
Journal:  JAMA Intern Med       Date:  2016-01       Impact factor: 44.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.